Phone: +45 27 51 26 22
1. Research area: Diabetic nephropathy. New risk markers for early signs of development of diabetic nephropathy. Short-term trials of different treatment modalities to prevent or delay progression of diabetic kidney disease.
2. Research area: Pharmacoepidemiology. How is treatment recommendations implemented, nationally and globally? Are there differences between the Nordic countries? Do differences in treatment patterns lead to different outcome?
Aim: Effect of dapagliflozin treatment on urinary peptide patterns.
Collaborators: AstraZeneca, Jens Faber (Denmark), Niklas R Jørgensen (Denmark), Erling B Petersen (Denmark), Harald Michak (Germany).
Aim: Allopurinol treatment to prevent diabetic nephropathy in type 1 diabetes.
Collaborators: Joslin Diabetes Center (USA), NIDDK (USA), JDRF (USA) and a number of North American universities and hospitals.
3. CVD REAL Nordic
Aim: Effect of SGLT2 inhibitors on real-life outcome in the Nordic nationwide healthcare registries.
Collaborators: AstraZeneca and Swedish, Norwegian, Finnish Universities.
Aim: Individualized prevention and treatment of diabetic nephropathy.
Collaborators: NovoNordisk Foundation, Joslin Diabetes Center (USA), University Medical Center Groningen (The Netherlands), Folkhälsan Helsinki (Finland).
Aim: Individualized prevention and treatment of diabetic nephropathy using urinary peptide patterns.
Collaborators: EU and a number of European universities.
6. DAPA CKD.
Aim: Dapagliflozin for patients with type 2 diabetes and nephropathy.